Innate Pharma SA IPHA
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2019 · data as of November 13, 2026
Innate Pharma SA (IPHA) is a healthcare company listed in the US with a market value of about $154M. In the twelve months to June 30, 2026 it had revenue of $5M and net income of -$52M, a net margin of -1121.6%.
Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -34% a year, a 5-year average ROIC of -190%.
About Innate Pharma SA
Innate Pharma SA is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2019. Revenue went from $53M in 2017 to $11M in 2025, a decline of about 18.2% a year. It was profitable in 1 of the last 9 years in our data.
Score: 0.2 / 5
Checks passed
- ROE above 15%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5M | $11M | $21M | $68M | $62M | $28M | $86M | $96M | $108M | $53M |
| Net income | -$52M | -$58M | -$51M | -$8M | -$62M | -$60M | -$79M | -$23M | $3M | -$58M |
| Free cash flow | -$27M | -$62M | -$8M | -$36M | -$21M | -$67M | -$65M | $38M | -$38M | -$61M |
| EPS (diluted) | $-0.56 | $-0.52 | $-0.46 | $-0.07 | $-0.55 | $-0.54 | $-0.70 | $-0.21 | $0.03 | $-0.52 |
| Net margin | -1121.6% | -546.1% | -245.9% | -12.3% | -100.7% | -213.8% | -91.7% | -24.3% | 3.2% | -109.9% |
| ROIC | — | — | -583.8% | -24.4% | -106.0% | -44.5% | 0.7% | 0.7% | 2.4% | -31.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Innate Pharma SA pay a dividend?
Not currently.
Is Innate Pharma SA a good stock to buy?
We do not give buy or sell advice. Innate Pharma SA scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.